STEMPOINT CAPITAL LP
NEW YORK, NY · CIK 1952142 · 13F filing filed 2024-08-13
SEC-registered investment adviser since 2022 · limited partnership
- Assets managed$761.3m
- Staff7 · 4 in investment roles
- Main clients (by assets)Private funds 85%, Companies 15%
- Private funds2 (2 hedge) · $584.4m gross assets
- Websitestempointcapital.com
- Form ADV · 2026-03-30SEC adviser record
- Legal entitySTEMPOINT CAPITAL LP (US)
- Kindhedge funds, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 2
$339.9m
reported value
-9.2% vs Q1 2024
42positions
55.4%in top 10
16 new
14 added
10 reduced
19 sold out
vs Q1 2024
Options: 1 call positions ($350.0k notional), 0 put positions (— notional) – listed below, not included above.
Holdings, Q2 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| SYNDAX PHARMACEUTICALS INC SNDX | $29.0m8.53% | Added +311.2k |
| ROIVANT SCIENCES LTD ROIV | $28.7m8.44% | Reduced -841.1k |
| IMMUNOVANT INC IMVT | $26.7m7.86% | Added +384.7k |
| CRINETICS PHARMACEUTICALS IN CRNX | $24.7m7.26% | Reduced -68.7k |
| MERUS N V MRUS | $17.1m5.02% | Added +54.8k |
| ARCELLX INC ACLX | $15.5m4.56% | Added +140.4k |
| AMICUS THERAPEUTICS INC FOLD | $14.8m4.36% | Reduced -52.1k |
| IMMUNOCORE HLDGS PLC IMCR | $11.5m3.38% | New |
| APPLIED THERAPEUTICS INC APLT | $10.3m3.04% | Added +194.3k |
| MERCK & CO INC MRK | $10.2m2.99% | New |
| GSK PLC GSK | $9.5m2.79% | New |
| AUTOLUS THERAPEUTICS PLC AUTL | $9.3m2.73% | Reduced -303.0k |
| ARCUTIS BIOTHERAPEUTICS INC ARQT | $9.0m2.64% | Reduced -1.2m |
| CABALETTA BIO INC CABA | $8.8m2.59% | Added +174.2k |
| KALVISTA PHARMACEUTICALS INC KALV | $8.7m2.55% | Reduced -424.3k |
| BIOHAVEN LTD BHVN | $8.1m2.38% | Added +149.8k |
| VISTAGEN THERAPEUTICS INC VTGN | $5.8m1.72% | Unchanged |
| IMMATICS N.V IMTX | $5.8m1.72% | Added +10.3k |
| DENALI THERAPEUTICS INC DNLI | $5.8m1.71% | New |
| INSMED INC INSM | $5.8m1.71% | Reduced -185.5k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $5.3m1.57% | New |
| LARIMAR THERAPEUTICS INC LRMR | $5.1m1.50% | Reduced -36.5k |
| TSCAN THERAPEUTICS INC TCRX | $4.9m1.45% | New |
| EDGEWISE THERAPEUTICS INC EWTX | $4.9m1.44% | New |
| CORBUS PHARMACEUTICALS HLDGS CRBP | $4.6m1.35% | New |
| FULCRUM THERAPEUTICS INC FULC | $4.3m1.27% | Added +289.4k |
| NURIX THERAPEUTICS INC NRIX | $4.2m1.25% | New |
| PYXIS ONCOLOGY INC PYXS | $4.0m1.17% | Reduced -591.5k |
| JANUX THERAPEUTICS INC JANX | $3.9m1.15% | Reduced -28.7k |
| IDEAYA BIOSCIENCES INC IDYA | $3.6m1.05% | Added +14.4k |
| SPYRE THERAPEUTICS INC SYRE | $3.5m1.04% | Added +88.2k |
| PERSPECTIVE THERAPEUTICS INC CATX | $3.4m1.01% | New |
| JASPER THERAPEUTICS INC JSPR | $3.3m0.96% | Added +14.6k |
| BLACK DIAMOND THERAPEUTICS I BDTX | $3.1m0.92% | New |
| VIGIL NEUROSCIENCE INC VIGL | $3.0m0.88% | New |
| NEUROGENE INC NGNE | $2.9m0.84% | New |
| SILENCE THERAPEUTICS PLC SLN | $2.4m0.70% | New |
| PROTARA THERAPEUTICS INC TARA | $2.0m0.60% | Added +815.7k |
| HELIX ACQUISITION CORP II BBOT | $2.0m0.60% | Unchanged |
| SURROZEN INC SRZN | $1.6m0.46% | New |
| PERCEPTIVE CAP SOLUTIONS COR FRNM | $1.5m0.44% | New |
| PRAXIS PRECISION MEDICINES I PRAX | $1.2m0.36% | Added +2.4k |
Sold out since Q1 2024
| Security | Value then |
|---|---|
| ELI LILLY & CO LLY | $11.7m15.1k shares |
| TARSUS PHARMACEUTICALS INC TARS | $8.1m222.3k shares |
| TOURMALINE BIO INC TRML | $6.3m274.2k shares |
| ANAPTYSBIO INC ANAB | $6.1m269.5k shares |
| SOLENO THERAPEUTICS INC SLNO | $5.0m115.8k shares |
| ACELYRIN INC | $4.8m714.8k shares |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $4.6m90.6k shares |
| ANNEXON INC ANNX | $4.3m605.1k shares |
| AVADEL PHARMACEUTICALS PLC AVDL | $3.8m223.7k shares |
| DISC MEDICINE INC IRON | $3.7m60.1k shares |
| TAYSHA GENE THERAPIES INC TSHA | $3.1m1.1m shares |
| ASTRIA THERAPEUTICS INC CATB | $2.7m230.3k shares |
| EFFECTOR THERAPEUTICS INC EFTR | $1.9m132.8k shares |
| NEWAMSTERDAM PHARMA COMPANY NAMS | $1.9m80.3k shares |
| CG ONCOLOGY INC CGON | $1.8m40.7k shares |
| ACHILLES THERAPEUTICS PLC | $1.7m1.4m shares |
| DIANTHUS THERAPEUTICS INC DNTH | $1.3m43.5k shares |
| CARGO THERAPEUTICS INC | $1.1m51.1k shares |
| KYVERNA THERAPEUTICS INC KYTX | $1.0m41.0k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC ARQT · Call | $350.0k500.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| CELLECTAR BIOSCIENCES INC CLRB · 13G · filed 2026-08-14 | 9.9%≈ $2.4m |
| XILIO THERAPEUTICS INC XLO · 13G · filed 2026-08-14 | 9.5%≈ $5.8m |
| XILIO THERAPEUTICS INC 13G · filed 2026-02-17 | 8.4% |
| SURROZEN INC SRZN · 13G · filed 2026-08-14 | 5.0%≈ $15.6m |